@article {7487,
	title = {Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial},
	journal = {Clinical Lymphoma, Myeloma and Leukemia},
	volume = {15},
	year = {2015},
	note = {Cited By :7Export Date: 21 February 2017},
	month = {2015},
	pages = {519 - 530},
	abstract = {Background Health-related quality of life (HRQoL) is an important element for consideration in treatment decisions in patients with relapsed/refractory multiple myeloma (RRMM). The pivotal MM-003 (A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone vs. High-Dose Dexamethasone in Patients With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study [NIMBUS]) randomized, open-label, multicenter, phase III trial demonstrated improved progression-free survival (PFS) and prolonged overall survival (OS) with pomalidomide (POM) plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in patients with RRMM in whom lenalidomide (LEN) and bortezomib (BORT) had failed. MM-003 also investigated HRQoL as a predefined secondary end point. Patients and Methods Recruited patients (n = 455) were refractory to their last treatment and had failed LEN and BORT after >= 2 consecutive cycles of each (alone or in combination). Eight clinically relevant and validated HRQoL domains from the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-MY20, and EQ-5D questionnaires were selected for analysis. Time to symptom worsening based on minimally important differences (MIDs) was calculated. Results Clinically meaningful improvements in HRQoL as determined by MIDs, regression analyses, and best response analyses were observed more frequently in patients receiving POM + LoDEX than in those receiving HiDEX. POM + LoDEX significantly extended median time to clinically meaningful worsening in HRQoL versus HiDEX in 4 HRQoL domains and demonstrated a trend in an additional 3 domains. Patients in the HiDEX arm experienced earlier HRQoL deterioration compared with those in the POM + LoDEX arm in each domain analyzed. Conclusion POM + LoDEX offer good clinical outcomes that lead to improved and prolonged HRQoL compared with HiDEX in patients with RRMM and end-stage disease. {\textcopyright} 2015 Elsevier Inc.},
	keywords = {Low dose dexamethasone, multiple myeloma, pomalidomide, Quality of Life, relapsed/refractory},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939563744\&doi=10.1016\%2fj.clml.2015.05.007\&partnerID=40\&md5=cd7fe52b918bc4fcc99e2a2504665a72},
	author = {Weisel, K. and Dimopoulos, M. and Song, K.W. and Moreau, P. and Palumbo, A. and Belch, A. and Schey, S. and Sonneveld, P. and Sternas, L. and Yu, X. and Amatya, R. and Gibson, C.J. and Zaki, M. and Jacques, C. and San Miguel, J.}
}
